CN111107873A - 用于降低生物制剂粘度的化合物 - Google Patents

用于降低生物制剂粘度的化合物 Download PDF

Info

Publication number
CN111107873A
CN111107873A CN201880057465.7A CN201880057465A CN111107873A CN 111107873 A CN111107873 A CN 111107873A CN 201880057465 A CN201880057465 A CN 201880057465A CN 111107873 A CN111107873 A CN 111107873A
Authority
CN
China
Prior art keywords
pharmaceutical composition
antibody
compound
seq
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880057465.7A
Other languages
English (en)
Chinese (zh)
Inventor
祝琳
N·Y·图森特
肖冬
P·瓦沙尔
R·S·卡什
A·巴克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of CN111107873A publication Critical patent/CN111107873A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/14—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880057465.7A 2017-09-05 2018-08-31 用于降低生物制剂粘度的化合物 Pending CN111107873A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762554134P 2017-09-05 2017-09-05
US62/554,134 2017-09-05
PCT/US2018/048995 WO2019050780A1 (en) 2017-09-05 2018-08-31 COMPOUNDS FOR REDUCING THE VISCOSITY OF BIOLOGICAL FORMULATIONS

Publications (1)

Publication Number Publication Date
CN111107873A true CN111107873A (zh) 2020-05-05

Family

ID=65634495

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880057465.7A Pending CN111107873A (zh) 2017-09-05 2018-08-31 用于降低生物制剂粘度的化合物

Country Status (11)

Country Link
US (2) US20200206350A1 (https=)
EP (1) EP3678700B1 (https=)
JP (1) JP2020532562A (https=)
KR (1) KR20200051687A (https=)
CN (1) CN111107873A (https=)
AU (1) AU2018328015A1 (https=)
BR (1) BR112020004325A2 (https=)
CA (1) CA3074565A1 (https=)
MX (1) MX2020002429A (https=)
RU (1) RU2020112302A (https=)
WO (1) WO2019050780A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022105782A1 (zh) * 2020-11-17 2022-05-27 中国医学科学院药物研究所 苯并异噻唑类化合物、及其制法和药物组合物与用途

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
AU2018263868A1 (en) 2017-05-02 2019-12-12 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
KR102885113B1 (ko) 2018-10-18 2025-11-13 머크 샤프 앤드 돔 엘엘씨 항-rsv 항체의 제제 및 그의 사용 방법
CN120842406A (zh) 2018-10-31 2025-10-28 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
CN113316458B (zh) 2018-11-07 2024-08-02 默沙东有限责任公司 抗lag3抗体和抗pd-1抗体的共制剂
KR102735988B1 (ko) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 치료 항체 제제
WO2022165001A1 (en) 2021-01-29 2022-08-04 Merck Sharp & Dohme Llc Compositions of programmed death receptor 1 (pd-1) antibodies and methods of obtaining the compositions thereof
KR20250006251A (ko) * 2022-04-29 2025-01-10 머크 샤프 앤드 돔 엘엘씨 항-ilt4 항체 또는 그의 항원-결합 단편의 제약 제제 및 사용 방법

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60136595A (ja) * 1983-12-01 1985-07-20 チバ‐ガイギー　アクチエンゲゼルシヤフト 置換エチレンジアミン誘導体、その製造方法及び該誘導体を含む医薬製剤
CN1448420A (zh) * 2002-04-01 2003-10-15 北京键凯科技有限公司 亲水性聚合物与丹参酮类药物的结合物以及包含该结合物的药物组合物
CN102532319A (zh) * 2011-12-28 2012-07-04 暨南大学 二硫键稳定的抗bFGF人源双链抗体及其制备方法与应用
US20120231972A1 (en) * 2009-03-19 2012-09-13 Golyshin Peter N Probe Compound for Detecting and Isolating Enzymes and Means and Methods Using the Same
CN102740888A (zh) * 2009-11-24 2012-10-17 奥尔德生物制药公司 Il-6抗体及其用途
CN102964588A (zh) * 2012-11-09 2013-03-13 河南工业大学 末端连接氨基苯丙酸的聚乙二醇的酸或活性酯的制法和应用
CN103402516A (zh) * 2010-06-17 2013-11-20 富津世生物技术有限公司 用作抗病毒药物的化合物、组合物及使用方法
CN103429264A (zh) * 2011-03-31 2013-12-04 默沙东公司 针对人程序性死亡受体pd-1的抗体的稳定制剂和有关的治疗
CN105705139A (zh) * 2013-09-11 2016-06-22 阿尔西亚治疗有限公司 包含水溶性有机染料的液体蛋白质制剂
US20160304607A1 (en) * 2015-04-17 2016-10-20 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-pd-1 antibody and another antibody

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5290489B2 (ja) 2001-11-08 2013-09-18 アッヴィ・バイオセラピューティクス・インコーポレイテッド Ｉｇｇ抗体の安定な液体医薬製剤
CN1798575A (zh) 2003-04-04 2006-07-05 健泰科生物技术公司 高浓度抗体和蛋白制剂
CN100543063C (zh) * 2006-04-03 2009-09-23 中国科学院过程工程研究所 氨基酸端基聚乙二醇及其制备方法
KR20130060227A (ko) 2010-05-03 2013-06-07 제넨테크, 인크. 단백질-함유 제제의 점도 감소에 유용한 조성물 및 방법
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60136595A (ja) * 1983-12-01 1985-07-20 チバ‐ガイギー　アクチエンゲゼルシヤフト 置換エチレンジアミン誘導体、その製造方法及び該誘導体を含む医薬製剤
CN1448420A (zh) * 2002-04-01 2003-10-15 北京键凯科技有限公司 亲水性聚合物与丹参酮类药物的结合物以及包含该结合物的药物组合物
US20120231972A1 (en) * 2009-03-19 2012-09-13 Golyshin Peter N Probe Compound for Detecting and Isolating Enzymes and Means and Methods Using the Same
CN102740888A (zh) * 2009-11-24 2012-10-17 奥尔德生物制药公司 Il-6抗体及其用途
CN103402516A (zh) * 2010-06-17 2013-11-20 富津世生物技术有限公司 用作抗病毒药物的化合物、组合物及使用方法
CN103429264A (zh) * 2011-03-31 2013-12-04 默沙东公司 针对人程序性死亡受体pd-1的抗体的稳定制剂和有关的治疗
CN102532319A (zh) * 2011-12-28 2012-07-04 暨南大学 二硫键稳定的抗bFGF人源双链抗体及其制备方法与应用
CN102964588A (zh) * 2012-11-09 2013-03-13 河南工业大学 末端连接氨基苯丙酸的聚乙二醇的酸或活性酯的制法和应用
CN105705139A (zh) * 2013-09-11 2016-06-22 阿尔西亚治疗有限公司 包含水溶性有机染料的液体蛋白质制剂
US20160304607A1 (en) * 2015-04-17 2016-10-20 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-pd-1 antibody and another antibody

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
"RN：1232311-14-6" *
"RN：1308943-73-8" *
HERMANS JOS，等: "Physicochemical Parameters Affecting the Electrospray Ionization Efficiency of Amino Acids after Acylation" *
MANZINI BARBARA，等: "Polymer-supported syntheses of oxo-crown ethers and derivatives containing α-amino-acid residues" *
PFEILSTICKER KONRAD等: "Isolation of the ethylene oxide 1,2-14C derived contents of cacao and their mass spectrometrically determined structure" *
ZHANG JING，等: "Synthesis and characterization of heterotelechelic poly(ethylene glycol)s with amino acid at one end and hydroxyl group at another end" *
胡楠;卞筱泓;许激扬;: "抗肿瘤活性多肽的研究现状" *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022105782A1 (zh) * 2020-11-17 2022-05-27 中国医学科学院药物研究所 苯并异噻唑类化合物、及其制法和药物组合物与用途

Also Published As

Publication number Publication date
CA3074565A1 (en) 2019-03-14
BR112020004325A2 (pt) 2020-10-06
EP3678700B1 (en) 2024-06-19
WO2019050780A1 (en) 2019-03-14
JP2020532562A (ja) 2020-11-12
RU2020112302A3 (https=) 2021-10-20
US20200206350A1 (en) 2020-07-02
US20220378916A1 (en) 2022-12-01
RU2020112302A (ru) 2021-10-06
KR20200051687A (ko) 2020-05-13
EP3678700A4 (en) 2021-04-28
EP3678700A1 (en) 2020-07-15
MX2020002429A (es) 2020-07-13
AU2018328015A1 (en) 2020-03-05

Similar Documents

Publication Publication Date Title
EP3678700B1 (en) Compounds for reducing the viscosity of biological formulations
US11518803B2 (en) Antagonist antibodies that bind to human TGFB1, TGFB2 and to TGFB3 and their use for the treatment of lung fibrosis
CN105968206B (zh) 抗erbb3抗体
NZ793343A (en) Anti- LAG-3 antibodies and compositions
CN108235685A (zh) Pd-1拮抗剂与egfr抑制剂的组合
US12534525B2 (en) Aqueous pharmaceutical composition of an anti-IL17A antibody and use thereof
KR20190006177A (ko) 암 치료용 항-pd1 및 항-lag3 항체
CN104245733A (zh) 针对受体的双重可变结构域免疫球蛋白
WO2015112822A1 (en) Antibody-drug conjugates targeting kit receptor and uses thereof
CA3245849A1 (en) ANTIBODY-DRUG CONJUGATE B7H4 AND ITS USE
CA3148776A1 (en) A dosing regimen for an ido inhibitor
JP2022550420A (ja) 抗ｐｄ－ｌ１抗原結合タンパク質及びその応用
CA3114955A1 (en) Combination therapy for cancer
JP2026502840A (ja) Ｃｄ４０結合分子の組成物及び医薬的使用
JP2023521228A (ja) 癌の併用療法
CN119546345A (zh) 使用抗cd22抗体寡核苷酸缀合物治疗癌症的方法
JP2025539457A (ja) 抗ｇｍ－ｃｓｆ抗体の液体医薬品製剤及びその用途
JP2024504250A (ja) Ｃｃｒ６抗体
WO2025228386A1 (en) Anti-entpd2 antibody and use thereof
WO2025056748A1 (en) Antibody-drug conjugate
WO2024263845A1 (en) Treatment of multiple myeloma
JP2025523845A (ja) 抗ｆｃｒｈ５／抗ｃｄ３二重特異性抗体による処置のための投薬
EA046015B1 (ru) Водная фармацевтическая композиция анти-il17a антитела и ее применение
OA20474A (en) Aqueous pharmaceutical composition of an anti-IL17A antibody and use thereof
HK40045175A (en) Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200505

WD01 Invention patent application deemed withdrawn after publication